Carboplatin

證據等級: L5

預測適應症: 10 個

Carboplatin: From Ovarian Cancer to Female Breast Carcinoma

One-Sentence Summary

Carboplatin is a platinum-based cytotoxic chemotherapy agent globally established as a first-line treatment for ovarian cancer, lung cancer, and other solid tumors — though no Philippine FDA registration is currently on file. The TxGNN model predicts it may be effective for Female Breast Carcinoma, with multiple completed Phase 3 RCTs and 20 publications — spanning triple-negative breast cancer (TNBC), HER2-positive, and BRCA-mutated subtypes — supporting this direction with the highest level of clinical evidence.

Quick Overview

Item	Content
Original Indication	Ovarian cancer and solid tumors (globally established; no Philippine FDA registration found)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.86%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Philippine regulatory record. Based on well-established pharmacology, Carboplatin is a second-generation platinum coordination compound that covalently binds to purine bases in DNA, forming intra- and inter-strand cross-links. These adducts physically block the movement of DNA polymerase and RNA polymerase, halting replication and transcription. When the resulting damage cannot be repaired, the cell commits to apoptosis via p53-dependent and p53-independent pathways. Unlike cisplatin, carboplatin is dosed using the Calvert formula (targeting an area under the curve rather than a flat body-surface-area dose), which reduces nephrotoxicity and neurotoxicity while preserving anticancer efficacy — making it the preferred backbone in many modern combination regimens.

The mechanistic bridge from its established oncology use to female breast carcinoma is scientifically well-grounded. Triple-negative breast cancer (TNBC) is enriched for BRCA1/2 germline and somatic mutations, producing homologous recombination deficiency (HRD). Cells lacking functional HR repair cannot efficiently resolve platinum-induced double-strand breaks, creating the same synthetic lethality that underpins carboplatin’s efficacy in BRCA-associated ovarian cancer. Beyond BRCA mutations, a broader “BRCAness” phenotype — characterised by promoter methylation of BRCA1 or other HR pathway alterations — expands the platinum-sensitive population in TNBC. In HER2-positive disease, combining carboplatin with anti-HER2 agents (trastuzumab, pertuzumab) exploits simultaneous HER2 pathway inhibition and DNA damage signalling, producing synergistic cytotoxicity that has been validated in the TCbHP and TCHP regimens.

Multiple completed Phase 3 trials now confirm carboplatin’s role as a standard component of breast cancer treatment. The Triple Negative Trial (NCT00532727) directly compared carboplatin against docetaxel in 400 patients with metastatic TNBC. The BROCADE3 study demonstrated significant progression-free survival improvement when veliparib was added to carboplatin+paclitaxel in BRCA1/2-mutated advanced breast cancer, with final overall survival data published in 2024. The GeparOcto (n=961) and TCHP (n=315) Phase 3 trials validated carboplatin-containing neoadjuvant regimens for high-risk early breast cancer. An ongoing 720-patient Phase 3 RCT (NCT03168880) continues to refine the carboplatin benefit in locally advanced TNBC. Together, these data represent some of the strongest drug repurposing validation in oncology, fully supporting the TxGNN model’s top-ranked prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00532727	Phase 3	Unknown	400	Triple Negative Trial: Direct RCT comparing carboplatin vs docetaxel as standard of care in metastatic ER−/PR−/HER2− breast cancer; primary goal to determine whether carboplatin has greater activity than a taxane in TNBC
NCT02125344	Phase 3	Completed	961	GeparOcto: Compared two dose-dense neoadjuvant regimens in high-risk early breast cancer; one arm included weekly paclitaxel/non-pegylated doxorubicin with carboplatin and dual HER2 blockade
NCT02003209	Phase 3	Completed	315	TCHP ± estrogen deprivation in HR+/HER2+ locally advanced breast cancer; evaluated whether adding estrogen deprivation to docetaxel/carboplatin/trastuzumab/pertuzumab improves pathologic complete response
NCT00047255	Phase 3	Completed	263	Docetaxel+trastuzumab with or without carboplatin as first-line therapy in HER2-amplified advanced breast cancer; established the TCH regimen benchmark used in HER2+ practice today
NCT03168880	Phase 3	Active, Not Recruiting	720	RCT of neoadjuvant weekly paclitaxel alone vs weekly paclitaxel+carboplatin in large operable or locally advanced TNBC; directly quantifies the benefit of adding carboplatin to taxane backbone
NCT05843292	Phase 4	Not Yet Recruiting	48	Short-term sintilimab (anti-PD-1) + taxane + carboplatin as neoadjuvant therapy in early-stage TNBC; Phase 4 deployment signals that this carboplatin-immunotherapy combination is already entering real-world practice
NCT00117442	Phase 2	Completed	61	Dose-intensive multi-cycle carboplatin/paclitaxel supported by pegfilgrastim-mobilised peripheral blood progenitor cells in advanced breast cancer; provided key dose-finding, efficacy, and kinetic data for the combination
NCT07327021	Phase 2	Recruiting	54	NOGA: MRI-guided neoadjuvant de-escalation strategy in stage II–III TNBC; carboplatin is part of the standard reference arm, reflecting its current guideline-compliant status
NCT06291064	Phase 2	Recruiting	85	TARMAC: Multi-omic biomarker study in Nigerian women with TNBC receiving epirubicin+cyclophosphamide followed by docetaxel+carboplatin; aims to identify resistance predictors for precision use of carboplatin
NCT02978495	Phase 2	Completed	154	NACATRINE: Prospective Phase 2 of neoadjuvant carboplatin specifically in TNBC in Brazil; assessed pCR rates and tolerability, contributing real-world data from a lower-middle-income country context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39671272	2025	RCT	JAMA	CamRelief trial: Camrelizumab (anti-PD-1) added to 4-drug neoadjuvant chemotherapy including platinum in early/locally advanced TNBC; demonstrates that platinum-containing backbones remain the scaffold for next-generation immunotherapy combinations
38309017	2024	Phase 3 RCT	Eur J Cancer	BROCADE3 final overall survival results: Veliparib + carboplatin/paclitaxel vs placebo + carboplatin/paclitaxel in BRCA1/2-mutated HER2-negative advanced breast cancer; confirms carboplatin as the indispensable backbone in BRCA-mutated disease
40593759	2025	Phase 2b RCT	Nature Communications	MUKDEN 06: ARX788+pyrotinib vs docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP) as neoadjuvant in HER2+ breast cancer; carboplatin-based regimen serves as the active standard comparator, confirming its benchmark status
25247558	2014	Meta-analysis	PLoS One	Meta-analysis confirming carboplatin significantly improves pathological complete response (pCR) in neoadjuvant TNBC; expands the argument for platinum use beyond BRCA-mutated patients to the broader TNBC population
16720915	2006	Review	Med Oncol	Comprehensive synthesis of preclinical synergy data and clinical trial results for paclitaxel-carboplatin in advanced breast cancer; established pharmacological rationale for the doublet that remains standard in multiple guidelines
40779028	2025	Phase I	Breast Cancer Res Treat	Carboplatin + gemcitabine + mifepristone (glucocorticoid receptor antagonist) in GR-positive breast and ovarian cancer; explores pharmacological strategy to reverse GR-mediated suppression of carboplatin-induced apoptosis
9516604	1998	Phase II	Oncology	Paclitaxel (175 mg/m²) + carboplatin (AUC 6) every 3 weeks as first-line for 66 patients with advanced breast cancer; one of the foundational studies defining dosing and response rates for this combination
8893899	1996	Review	Semin Oncol	Foundational evaluation of carboplatin single-agent activity and paclitaxel-carboplatin synergy in advanced breast cancer; laid the conceptual and clinical groundwork for combination trials still running today
39944694	2025	Bioinformatics/Cohort	Front Immunol	DNA damage repair (DDR) gene signature associated with carboplatin resistance and immune infiltration in breast cancer; identifies prognostic markers and immune evasion mechanisms relevant for precision patient selection
33256829	2020	Phase II	Breast Cancer Res	Phase II trial of carboplatin + bevacizumab in breast cancer brain metastases; evaluated safety and antitumor activity, demonstrating that carboplatin’s CNS penetration is sufficient for activity in the metastatic brain setting

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Platinum coordination compound / Alkylating-like agent)
Myelosuppression Risk	High — dose-limiting toxicity is thrombocytopenia (platelet nadir typically Day 21, AUC-dependent); neutropenia and anaemia are also frequent; requires CBC monitoring before each cycle and dose adjustment for marrow recovery
Emetogenicity Classification	Moderate to High (moderate at standard AUC 5–6; high at escalated doses used in transplant conditioning)
Monitoring Items	CBC with differential and platelet count prior to each cycle; serum creatinine and creatinine clearance (Cockcroft-Gault or measured GFR) for Calvert formula dosing; audiometry for high-dose or cumulative regimens
Handling Protection	Must follow cytotoxic drug handling regulations; preparation in a Class II biological safety cabinet under negative pressure; full PPE (double gloves, gown, eye protection) required for preparation and administration; cytotoxic waste disposal protocols apply

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Carboplatin achieves the highest evidence level (L1) for female breast carcinoma, supported by at least four completed Phase 3 RCTs across TNBC (NCT00532727, NCT02125344) and HER2-positive (NCT00047255, NCT02003209) subtypes, plus an ongoing 720-patient Phase 3 trial (NCT03168880). The mechanistic rationale — platinum-induced DNA cross-links exploiting homologous recombination deficiency in BRCA-mutated and BRCAness tumors — represents one of the most rigorously validated predictive biomarker relationships in oncology.

To proceed, the following is needed:

Philippine FDA registration: Carboplatin currently has zero registered products in the Philippines; product registration or a hospital/compassionate-use framework is required before clinical procurement
Mechanism of action documentation: Retrieve the full pharmacology entry from the DrugBank API (DB00958) to complete the regulatory evidence dossier
Biomarker-driven patient selection strategy: Define upfront testing for BRCA1/2 mutation status and HRD score to identify which breast cancer subtype (TNBC vs HER2+ vs BRCA-mutated HR+) benefits most, avoiding use in biomarker-unselected luminal A/B disease where benefit is not established
Safety monitoring protocol: Formalise renal function monitoring for Calvert-formula dosing, myelosuppression management (G-CSF policy, platelet transfusion thresholds), and cumulative ototoxicity surveillance for high-dose regimens
YMYL disclaimer: These predictions are provided for research reference only and do not constitute medical advice; all repurposing candidates require clinical validation and physician oversight before application in patient care
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.